Evidence map›Paper›PMID 37153026›Full record

ArticleJournal of cancer epidemiology2023

A Retrospective Observational Study on Disease Characteristics and Treatment Patterns of Giant Cell Tumor of the Bone in China.

Hairong Xu, Yuan Li, Tao Wang, Weifeng Liu, Ke Ma, Yongkun Yang, Zhen Huang, Chuang Li, Xiaohui Niu

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hairong XuDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Yuan LiDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Tao WangDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Weifeng LiuDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Ke MaDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Yongkun YangDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Zhen HuangDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Chuang LiAmgen China, Shanghai, China.ORCID https://orcid.org/0009-0001-1683-7652
Xiaohui NiuDepartment of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.ORCID https://orcid.org/0000-0001-7782-6669
Beijing Tian Tan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Giant cell tumor of the bone (GCTB) is associated with considerable morbidity. As GCTB epidemiological data for China are limited, this study is aimed at describing the disease characteristics of GCTB in China and establishing the historical context for its treatment before recent advances in treatment options. Methods: The disease characteristics, treatment patterns, and local GCTB recurrence rate after primary surgery for GCTB were evaluated in this single-center, retrospective, noninterventional, observational study of patients treated for GCTB at Ji Shui Tan Hospital, Beijing, from 2009 to 2016 based on medical chart review. Patients with unmet need were defined as those whose surgical treatment was difficult or who had to undergo high-morbidity surgery. Results: Among the 668 patients with a primary GCTB diagnosis, 578 (86.5%) of target lesions were in the extremities, and 89 (13.3%) were in the pelvic or axial bone. Of these, 173 (25.9%) were characterized as having an unmet need. Almost all GCTB patients received surgical treatment at both primary diagnosis (666/668 (99.7%)) and last disease recurrence (196/200 (98.0%)). Additionally, about one-third of patients received nonsurgical treatment at primary diagnosis (205/668 (30.7%)) and disease recurrence (67/200 (33.5%)), with neoadjuvant therapy being the most common treatment. The rate of high-morbidity surgery increased for recurrent disease (65/200 (32.5%)) compared with primary diagnosis (111/668 (16.6%)). The 2-year cumulative incidence of postoperative disease recurrence was 29.2%, in line with rates observed in prior studies. Conclusion: As many patients with primary and recurrent disease received high-morbidity surgery, more effective treatments are needed.

Identifiers

PMID37153026
PMCPMC10162870
OpenAlexW4367302301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.